Intellia Therapeutics, Inc. (LON: 0JBU)

Market Cap	910.48M
Revenue (ttm)	32.15M
Net Income (ttm)	-389.68M
Shares Out	n/a
EPS (ttm)	-4.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,150
Average Volume	15,551
Open	11.20
Previous Close	9.84
Day's Range	11.07 - 11.41
52-Week Range	11.07 - 46.91
Beta	n/a
RSI	38.10
Earnings Date	Feb 20, 2025

About Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2014
• Employees: 526
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JBU

Financial Performance

In 2023, Intellia Therapeutics's revenue was $36.28 million, a decrease of -30.40% compared to the previous year's $52.12 million. Losses were -$481.19 million, 1.48% more than in 2022.

Financial numbers in USD